HOUSTON--(BUSINESS WIRE)-- Vapogenix, a clinical-stage company developing a new class of topical non-opioid, lidocaine-free analgesics, today announced it has been awarded a $1.5M Phase II Small Business Innovation Research (SBIR) grant (Award No. R44AR074838) from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) at the US National Institutes of Health.
HEIDELBERG, GERMANY / ACCESSWIRE / July 28, 2020 / Apogenix, a biopharmaceutical company developing next generation immunotherapeutics, announced today that it has received regulatory approval to start a clinical phase II trial with asunercept in COVID-19 patients in Russia. The ASUNCTIS trial will be a multi-center, randomized, controlled, open-label trial to assess the efficacy and safety of asunercept in patients with severe COVID-19 disease.